H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Veru Inc (VERU) today and set a price target of $4.50. The company’s shares closed yesterday at $1.58.
Selvaraju said:
“Our price target is derived from an estimated market value of the firm at $301M. This includes a discounted cash flow-based asset value of $309M for FC2 and TADFIN, excluding $8M debt and using a 15% discount rate, 0% terminal growth rate and 80% probability of success for TADFIN. Investment risks include: (1) failure of FC2 or TADFIN to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of TADFIN to obtain regulatory approval; (3) failure of other pipeline candidates; and (4) potential dilution risk.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -1.8% and a 34.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Veru Inc is a Moderate Buy with an average price target of $4.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.37 and a one-year low of $1.18. Currently, Veru Inc has an average volume of 159.8K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.
